Bénédicte F. Py

This study identifies CRY-NLRP3 complexes as a circadian checkpoint that modulates inflammasome activation and drug response, showing time-of-day effects on inflammation and drug efficacy.

This paper characterizes BAL-0028, a novel NLRP3 inhibitor with a distinct binding site and mechanism, showing potent inhibition of human and primate NLRP3 and efficacy in a peritonitis model.

This paper identifies and characterizes BAL-1516, a CNS-penetrating NLRP3 inhibitor that blocks inflammasome formation and shows potential for treating neuroinflammatory diseases.

This study functionally characterizes 34 NLRP3 variants associated with CAPS, identifying functional diversity and inhibitor sensitivity, with implications for diagnosis and drug development.